Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Patent and Trademark Office has granted a patent for BioMarck Pharmaceuticals' core technology in a novel treatment for respiratory diseases associated with mucus hypersecretion and inflammation, currently in clinical trials.
Subscribe to our email newsletter
BioMarck Pharmaceuticals has licensed worldwide exclusive rights for this patent and related patents from North Carolina State University. The new patent provides broad protection for a series of first-in-class mucus inhibiting peptides and the methods of treatment for a variety of pulmonary diseases involving mucus hypersecretion. A European patent and a series of international patents are allowed while others are pending.
Indu Parikh, BioMarck’s president and chief scientific officer, said: “BioMarck believes that this patent significantly strengthens its overall intellectual property portfolio. Our treatment is designed to address a variety of pulmonary diseases, including chronic obstructive pulmonary disease, asthma and chronic rhinitis, and possibly sinusitis and cystic fibrosis. Each of these market segments has clear needs for a new and effective drug.”